Title |
Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B cell non-Hodgkin lymphoma |
|---|---|
Involved |
Frank Kroschinsky (Verfasser)
Jan Moritz Middeke (Verfasser) Martin Janz (Verfasser) Georg Lenz (Verfasser)
Mathias Witzens-Harig (Verfasser)
Reda Bouabdallah (Verfasser) Paul La Rosée (Verfasser) Andreas Viardot (Verfasser) Gilles Salles (Verfasser) Seok Jin Kim (Verfasser) Tae Min Kim (Verfasser) Oliver Ottmann (Verfasser) Joerg Chromik (Verfasser) Anne-Marie Quinson (Verfasser) Ute von Wangenheim (Verfasser) Ute Burkard (Verfasser) Andreas Berk (Verfasser) Norbert Schmitz (Verfasser) SpringerLink (Online service) (Sonstige) |
Published in |
Investigational new drugs : an interdisciplinary journal for clinicians and scientists 39, 1, 23.6.2020, date:2.2021, Seite 285-286 |
Published |
2020 |
Language |
|
Country |
|
Topic |
|
Subject |
Oncology. |
DDC notation |
|
Persistent identifier |
urn:nbn:de:101:1-2021032519180109588948 (URN) |
Record ID |
1230122664 |
Please note
The beta version does not yet contain all functions and information of the DNB portal catalogue. If you are missing information or want to order a medium, please visit the page in the DNB portal catalogue via the following link: